finance.yahoo.com ·
Biocryst Pharmaceuticals Q1 Earnings Call
Topic context
This topic has been covered 401266 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedBioCryst Pharmaceuticals (PHARMA_BIOTECH) reported strong ORLADEYO revenue growth but faces a manufacturing delay for its pediatric formulation, which may affect future revenue expansion. The Navenibart trial progress is positive but not yet commercial. The impact is company-specific, with no direct commodity or broad sector mechanism. Weak commercial mechanism: manufacturing issue is not safety-related and guidance unchanged.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 net revenue from ORLADEYO $148.3M, up 21% YoY (ex-Europe divestiture).
- Manufacturing issue delays pediatric formulation launch; not FDA/safety related.
- ALPHA-ORBIT trial for Navenibart enrollment ~145 patients; completion expected by end of next month.
- Cash balance ~$261M at quarter end.
- FY2026 ORLADEYO revenue guidance maintained at $625-645M.
ORLADEYO revenue growth remains stable, but manufacturing delay for pediatric formulation leads to flat performance in 24-48h.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHshort
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
fool.com
Canaan Can Q1 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
finance.yahoo.com
Capsovision Q1 Earnings Call Highlights
fool.com